CBIO — Crescent Biopharma, Inc. stock price, charts and financials

QT68Crescent Biopharma, Inc.

Crescent Biopharma, Inc. (NASDAQ: CBIO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
16.89
+0.12+0.72%
OverviewShort InterestFilings
CBIOQT68Crescent Biopharma, Inc.·NASDAQ
16.89+0.72%
News
Up 0.7% — Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR) (defenseworld.net).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RAPP-3.58%$40.45GHRS-1.60%$28.26MESO+1.75%$15.13ZYME-3.31%$26.57AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83GPCR-0.28%$35.00
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand37.14MPerf Week-12.98%
Market Cap627.36MForward P/E-EPS next Y-2.91Insider Trans2.94%Shs Float18.51MPerf Month-2.48%
Enterprise Value457.21MPEG-EPS next Q-0.67Inst Own-Short Float8.54%Perf Quarter-4.52%
Income-198.25MP/S52.79EPS this Y-Inst Trans-Short Ratio10.17Perf Half Y59.04%
Sales11.88MP/B3.16EPS next Y-5.24%ROA-89.18%Short Interest3.17MPerf YTD42.41%
Book/sh-P/C-EPS next 5Y-ROE-97.77%52W High27.41 -38.38%Perf Year31.95%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-102.29%52W Low8.72 93.69%Perf 3Y-88.43%
Dividend Est.-EV/EBITDA-Sales past 3/5Y- 1.92%Gross Margin-Volatility9.95% 7.80%Perf 5Y-92.49%
Dividend TTM-EV/Sales38.48EPS Y/Y TTM89.37%Oper. Margin-1417.74%ATR (14)1.47Perf 10Y-97.68%
Dividend Ex-DateJan 13, 2023Quick Ratio9.66Sales Y/Y TTM-Profit Margin-1371.51%RSI (14)43.09Recom2.36
Dividend Gr. 3/5Y-Current Ratio9.66EPS Q/Q84.99%SMA20-8.12%Beta1.25Target Price31.25
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA50-0.91%Rel Volume7.73Prev Close16.77
Employees44LT Debt/Eq0.00EarningsNov 05SMA2007.73%Avg Volume403.90KPrice16.89
IPO DateJan 10, 2014Option/ShortYes / YesEPS/Sales Surpr.-0.58% 180.00%Net Debt/EBITDA1.04Volume3,123,507Change0.72%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26DowngradeHC Wainwright & Co.Buy → Neutral
Feb-26-26ReiteratedStifel NicolausBuy$32 → $29
Jan-28-26InitiatedPiper SandlerOverweight$35
Jan-21-26InitiatedGuggenheimBuy$35
Dec-04-25ReiteratedStifel NicolausBuy$28 → $32
Aug-25-25InitiatedJefferiesBuy$26
Jul-26-24DowngradeTD CowenBuy → Hold
May-06-24DowngradeHC Wainwright & Co.Buy → Neutral
Nov-12-21UpgradeJefferiesHold → Buy
Aug-05-19DowngradePiper JaffrayOverweight → Neutral
Latest News· Times ET
Sep-16-26
Sep-16-2611:32PM
Head-To-Head Comparison: Crescent Biopharma (NASDAQ:CBIO) vs. Vir Biotechnology (NASDAQ:VIR)defenseworld.net
Sep-15-26
Sep-15-2601:11AM
Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
Sep-14-26
Sep-14-2604:38AM
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price TargetBenzinga
Sep-09-26
Sep-09-2612:15PM
Crescent Biopharma Announces Grants of Inducement Awardsglobenewswire.com
Sep-03-26
Sep-03-2604:51PM
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is SoldYahoo
03:30AM
Crescent Biopharma to Present at September Investor Conferencesglobenewswire.com
Aug-27-26
Aug-27-2605:21AM
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price TargetBenzinga
Aug-03-26
Aug-03-2603:30AM
Crescent Biopharma Announces Grants of Inducement Awardsglobenewswire.com
Jul-30-26
Jul-30-2604:14AM
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) EstimateBenzinga
03:35AM
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlightsglobenewswire.com
Jul-23-26
Jul-23-2612:15PM
Crescent Biopharma Announces Grants of Inducement Awardsglobenewswire.com
Jul-16-26
Jul-16-2612:01PM
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Sharesglobenewswire.com
Jul-14-26
Jul-14-2605:45PM
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrantsglobenewswire.com
12:02PM
Crescent Biopharma Commences Offering Of Common Stock, Pre-Funded Warrants; Terms UndisclosedBenzinga
12:01PM
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrantsglobenewswire.com
Company

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue1100——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit1100——————
Selling, General and Administrative Excl. Other251619——————
Research and Development1382820——————
Other Operating Expense060——————
Operating Income-153-50-39——————
Interest Expense210——————
Unusual Expense
—————————
Non-Operating Income (Expense)322——————
Net Income Before Taxes-152-49-37——————
Income Taxes200——————
Consolidated Net Income-154-49-37——————
Net Income From Continuing Operations-154-49-37——————
Net Income-154-49-37——————
EPS (Recurring)-14.78-63.22-58.25——————
EPS (Basic, Before Extraordinaries)-14.78-63.22-58.25——————
EPS (Diluted)-14.78-63.22-58.25——————
EBITDA-150-44-39——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio10.78————————
Gross Margin100.00————————
Operating Margin-1,390.91————————
Net Margin-1,400.00————————
Shares Outstanding1011——————
Market Capitalization11925236——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.69$23.82$17.96$12.10$6.23● Close Price0.00M4.56M9.12M13.68M18.24MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Brumm Joshua TChief Executive OfficerSep 18 '26Sale16.717,837130,956271,765Sep 18
McNeill JonathanPresident and COOSep 18 '26Sale16.713,83964,150134,588Sep 18
Brumm Joshua TChief Executive OfficerSep 16 '26Sale17.901,61028,819279,602Sep 18
Lynch RyanSee RemarksSep 16 '26Sale17.902404,29613,631Sep 18
McNeill JonathanPresident and COOSep 16 '26Sale17.9073113,085138,427Sep 18
Scalzo Richard WilliamChief Financial OfficerSep 16 '26Sale17.9056810,16719,730Sep 18
Bispham Barbara HarlinSee RemarksSep 16 '26Sale17.9062011,09818,710Sep 18
Im Ellie EunkyungChief Medical OfficerSep 16 '26Sale17.9062311,15221,446Sep 18
Pinkas JanChief Scientific OfficerSep 16 '26Sale17.9065811,77821,581Sep 18
Fairmount Funds Management LLCdirector, 10 percent owner:Jul 16 '26Buy8.971,379,34712,375,5513,601,316Jul 20
Scalzo Richard WilliamChief Financial OfficerJun 22 '26Sale17.991,11220,00520,298Jun 23
Bispham Barbara HarlinSee RemarksJun 22 '26Sale17.991,21821,91219,330Jun 23
Im Ellie EunkyungChief Medical OfficerJun 22 '26Sale17.991,21921,93022,069Jun 23
McNeill JonathanPresident and COOJun 22 '26Sale17.9920,549369,677139,158Jun 23
Lynch RyanSee RemarksJun 22 '26Sale17.994658,36513,871Jun 23
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.